Latest news and press releases about Jupiter Neurosciences, Inc. (JUNS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
Price
| Price | $2.93 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -4.27 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 747.33% |
| Return on Invested Capital | -709.40% |
| Return on Assets | -247.39% |
| Gross Margin | 88.34% |
| Operating Margin | -15166.68% |
| Net Margin | -14220.12% |
Related companies: ABVC · ALGS · FGEN · GNTA · GRCE · KZR · MRSN
Explore sector: Healthcare · Biotechnology
More sections of JUNS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks